tetano
Editor, Senior Moderator
Therapie. 2010 11-12;65(6):533-541. Epub 2010 Dec 23.
Safety Review: Squalene and Thimerosal in Vaccines.
Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P.
Laboratoire de Pharmaco-Chimie Radicalaire, Facult? de Pharmacie, Universit?s d'Aix-Marseille I, II et III, UMR-CNRS 6264, Laboratoire Chimie Provence, Marseille, France.
Abstract
Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper is to assess the safety in using these adjuvants and preservative reviewing data of clinical trials relative to wich formulation includes these compounds. In the current state of knowledge, these vaccines have proved to be effective even though they more frequently give local adverse events than non-adjuvanted influenza vaccines. Systemic side effects are generally not serious. In the studies, adjuvanted vaccines do not increase neither the risk of Guillain Barre syndrome nor auto-immune diseases. There is no convincing evidence that exposure to thimerosal in vaccines had any deletorious effect on physiological outcome.
? 2010 Soci?t? Fran?aise de Pharmacologie et de Th?rapeutique.
PMID: 21176760 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21176760
Safety Review: Squalene and Thimerosal in Vaccines.
Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P.
Laboratoire de Pharmaco-Chimie Radicalaire, Facult? de Pharmacie, Universit?s d'Aix-Marseille I, II et III, UMR-CNRS 6264, Laboratoire Chimie Provence, Marseille, France.
Abstract
Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper is to assess the safety in using these adjuvants and preservative reviewing data of clinical trials relative to wich formulation includes these compounds. In the current state of knowledge, these vaccines have proved to be effective even though they more frequently give local adverse events than non-adjuvanted influenza vaccines. Systemic side effects are generally not serious. In the studies, adjuvanted vaccines do not increase neither the risk of Guillain Barre syndrome nor auto-immune diseases. There is no convincing evidence that exposure to thimerosal in vaccines had any deletorious effect on physiological outcome.
? 2010 Soci?t? Fran?aise de Pharmacologie et de Th?rapeutique.
PMID: 21176760 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21176760